Prosecution Insights
Prosecution Insights
11 pending office actions • 10 clients • 11 examiners • 9 art units • 0 of 11 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (27%) |
| §102 only | 3 (27%) |
| Double-patenting + other | 1 (9%) |
| No statute on record | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 63.5% | +38.8% |
| ULLMAN, AARON RAFANAN | 1 | — | — |
| MCKNIGHT, CIARA A | 1 | 61.8% | +34.7% |
| BRAUN, MADELINE E | 1 | 68.0% | +24.9% |
| SHOWALTER, ALEXANDER KEITH | 1 | 52.1% | +53.0% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.3% | +24.5% |
| BELYAVSKYI, MICHAIL A | 1 | 63.8% | +27.5% |
| WELLS, LAUREN QUINLAN | 1 | 45.6% | +58.7% |
| DIBRINO, MARIANNE | 1 | 43.3% | +41.2% |
| SIMMONS, CHRIS E | 1 | 34.6% | +19.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | BELYAVSKYI, MICHAIL A | 393d overdue |
| 17634963 | GENETICALLY ENGINEERED CELLS AND USES THEREOF | DIBRINO, MARIANNE | 70d overdue |
| 17806689 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | SIMMONS, CHRIS E | 15d overdue |
| 18255855 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SHOWALTER, ALEXANDER KEITH | 9d overdue |
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | BRAUN, MADELINE E | 5d |
| 18245125 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | WHITE, DAWANNA SHAR-DAY | 12d |
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | MCKNIGHT, CIARA A | 13d |
| 17999843 | BIARYLSULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING FIBROTIC LUNG DISEASE | WELLS, LAUREN QUINLAN | 13d |
| Client (Assignee) | Pending OAs |
|---|---|
| BIOTHERYX, INC. | 2 |
| Vivavision Biotech, Inc. | 1 |
| NUMAFERM GmbH | 1 |
| Bielefeld University | 1 |
| Eubulus Biotherapeutics | 1 |
| CRAGE MEDICAL CO., LIMITED | 1 |
| NovoMedix, LLC | 1 |
| Cure Genetics Co., Limited | 1 |
| IC-MedTech Corp. | 1 |
| CARsgen Life Sciences Co., Ltd | 1 |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1622 | 2 |
| 1628 | 1 |
| 1656 | 1 |
| 1624 | 1 |
| 1627 | 1 |
| 1644 | 1 |
| 1641 | 1 |
| 1632 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18542628 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | DPOther | Non-Final OA | 71d | Pending | Dec 16, 2023 |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | Vivavision Biotech, Inc. | ULLMAN, AARON RAFANAN | 1628 | §102 | Non-Final OA | 84d | Pending | Nov 16, 2023 |
| 18550967 | FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES | Numaferm GmbH | MCKNIGHT, CIARA A | 1656 | Other | Non-Final OA | 13d | Pending | Sep 17, 2023 |
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Universitat Bielefeld | BRAUN, MADELINE E | 1624 | §103 | Non-Final OA | 5d | Pending | Aug 18, 2023 |
| 18255855 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Eubulus Biotherapeutics Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §102 | Non-Final OA | 9d overdue | Pending | Jun 02, 2023 |
| 18245125 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | WHITE, DAWANNA SHAR-DAY | 1627 | Other | Final Rejection | 12d | Pending | Mar 13, 2023 |
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | Crage Medical Co., Limited | BELYAVSKYI, MICHAIL A | 1644 | Other | Non-Final OA | 393d overdue | Pending | Feb 24, 2023 |
| 17999843 | BIARYLSULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING FIBROTIC LUNG DISEASE | NovoMedix, LLC | WELLS, LAUREN QUINLAN | 1622 | Other | Final Rejection | 13d | Pending | Nov 23, 2022 |
| 17634963 | GENETICALLY ENGINEERED CELLS AND USES THEREOF | Cure Genetics Co., Limited | DIBRINO, MARIANNE | 1641 | §102 | Non-Final OA | 70d overdue | Pending | Nov 09, 2022 |
| 17806689 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | Ic-Medtech Corp. | SIMMONS, CHRIS E | 1622 | §103 | Final Rejection | 15d overdue | Pending | Jun 13, 2022 |
| 17623481 | CELL FOR RESISTING TRANSPLANT REACTION AND METHOD | Carsgen Life Sciences Co., Ltd. | TRAN, KHOA NHAT | 1632 | §103 | Non-Final OA | 4d overdue | Pending | Dec 28, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial